Article Details
Retrieved on: 2018-01-29 17:45:00
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
<div>The stock has risen by over 40% since I stated that it was "worth much more than the present share price". The EMA setback for Puma Biotechnology's neratinib serves to highlight the differentiated profile of tucatinib and the possibility of becoming a favored HER-2 targeted agent if it reaches approval.</div>
Article found on:
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here